Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers

ConclusionsThe incremental cost-effectivenes ratio was well below the applicable threshold for diseases with a high burden of disease in the Netherlands ( €80,000). At this threshold, larotrectinib was estimated to be a cost-effective treatment for patients with tropomyosin receptor kinase fusion-positive cancer compared with current standard of care in the Netherlands.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research